Synairgen slumps by a third as AstraZeneca ditches asthma drug study

Synairgen Plc said its partner AstraZeneca Plc stopped a mid-stage study for testing Synairgen’s drug candidate as a potential treatment for severe asthma, putting the brakes on the lead product in Synairgen’s pipeline.